Crosstalk Between the Spleen and Other Organs/Systems: Downstream Signaling Events DOI Creative Commons
Giovanni Tarantino,

Vincenzo Citro

Immuno, Journal Year: 2024, Volume and Issue: 4(4), P. 479 - 501

Published: Nov. 8, 2024

The aim of this review was to gather pieces information from available critically evaluated published articles concerning any interplay in which the spleen could be involved. For many years, has been alleged as an unnecessary biological structure, even though splenomegaly is objective finding illnesses. Indeed, previous opinion completely changed. In fact, not a passive participant or simple bystander relationship that exists between immune system and other organs. Recently, it evidenced preclinical clinical studies there are close associations parts body, leading various spleen–organ axes. Among them, gut–spleen axis, liver–spleen gut–spleen–skin brain–spleen cardio-splenic axis most explored present medical literature. Such recent sources evidence have led revolutionary new ideas being developed about spleen. What more, these observations may enable identification novel therapeutic strategies targeted at current diseases. time come make clear superfluous body part, while health operators physicians should pay more attention organ. much work remains performed assess further roles structure play.

Language: Английский

Artificial intelligence and obesity management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 DOI Creative Commons
Harold Bays, Angela Fitch, Suzanne Cuda

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 6, P. 100065 - 100065

Published: April 20, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of Artificial Intelligence, focused on the management patients with obesity.

Language: Английский

Citations

68
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Children with Obesity: An Obesity Medicine Association (OMA) and Expert Joint Perspective 2025 DOI Creative Commons

Jennifer Panganiban,

Mohit Kehar, Samar H. Ibrahim

et al.

Obesity Pillars, Journal Year: 2025, Volume and Issue: 14, P. 100164 - 100164

Published: Feb. 1, 2025

This Obesity Medicine Association (OMA) Expert Joint Perspective examines steatotic liver disease (SLD), which is composed of metabolic dysfunction-associated (MASLD), and steatohepatitis (MASH) in children with obesity. The prevalence obesity increasing, rates have tripled since 1963 from 5 % to now 19 US affected 2018. MASLD, the most common seen children, can be a precursor development Type 2 Diabetes (T2DM) primary reason for transplant listing young adults. We must vigilant prevention treatment MASLD childhood prevent further progression. joint clinical perspective based upon scientific evidence, peer expertise. medical literature was reviewed via PubMed search appropriate articles were included this review. work formulated collaboration eight hepatologists/gastroenterologists expertise two physicians OMA. authors who are experts field, determined sentinel questions often asked by clinicians regarding They created consensus guideline on screening, diagnosis, associated children. comorbidity increasing problem that needs addressed urgently. It well known chronic continue these diseases as adults, leads reduced life expectancy, quality life, healthcare financial burden. paper recommend healthy weight reduction not only through lifestyle modification but pharmacotherapy bariatric surgery. Therefore, guidance reviews available therapies achieve reverse progressive fibrosis, disease.

Language: Английский

Citations

2
Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study DOI Creative Commons
Quentin M. Anstee,

Tina Landsvig Berentzen,

Louise Maymann Nitze

et al.

The Lancet Regional Health - Europe, Journal Year: 2023, Volume and Issue: 36, P. 100780 - 100780

Published: Dec. 19, 2023

The Fibrosis-4 Index (FIB-4) is used as a non-invasive tool for the presence of advanced liver fibrosis in metabolic dysfunction-associated steatotic disease and type 2 diabetes. However, evidence an association between FIB-4 risk mortality and/or liver-related clinical outcomes limited. aim this study was to investigate subsequent events, cardiovascular all-cause individuals with obesity diabetes examined routine general practice.

Language: Английский

Citations

39
Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 DOI Creative Commons
Harold Bays,

Shagun Bindlish,

Tiffany Lowe Clayton

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 5, P. 100056 - 100056

Published: Jan. 28, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.

Language: Английский

Citations

32
Clinical review: Guide to pharmacological management in pediatric obesity medicine DOI Creative Commons
Valerie O’Hara, Suzanne Cuda, Roohi Y. Kharofa

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 6, P. 100066 - 100066

Published: April 27, 2023

Newer pharmacotherapy agents (anti-obesity medication [AOM]) are revolutionizing the management of children and adolescents with obesity. Previously, treatment based on intensive behavioral therapy involved many patient family contact hours yielded improvements in obesity status 1-3 percent 95th percentile body mass index (BMI). AOMs yielding more clinically significant improvement 5-18 percent. This review provides guidance for practitioners care who frequently have complex medical health needs. Specifically, we discuss use newer these patients.

Language: Английский

Citations

12
A Review of the Effects of Fucoxanthin on NAFLD DOI Open Access
Nor Hafiza Sayuti, Khairul Najmi Muhammad Nawawi, Jo Aan Goon

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(8), P. 1954 - 1954

Published: April 19, 2023

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic disease. Fucoxanthin, a red-orange marine carotenoid, found in natural seaweeds with high antioxidant activity and several other remarkable biological features. The aim this review to gather evidence positive benefits fucoxanthin on NAFLD. Fucoxanthin provides an extensive list physiological properties, such as hepatoprotective, anti-obesity, anti-tumor, anti-diabetes addition anti-inflammatory properties. This focuses published research preventative effects NAFLD from perspective human clinical trials, animal experiments vivo, vitro cell investigations. Using variety experimental designs, including treatment dosage, experiment model, periods, were demonstrated. Fucoxanthin’s activities outlined, emphasis its therapeutic efficacy showed beneficial modulating lipid metabolism, lipogenesis, acid oxidation, adipogenesis, oxidative stress A deeper comprehension pathogenesis essential for development novel effective strategies.

Language: Английский

Citations

11
Comprehensive care for patients with obesity: An Obesity Medicine Association Position Statement DOI Creative Commons
Angela Fitch,

Lydia Alexander,

C. Brown

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 7, P. 100070 - 100070

Published: May 18, 2023

Language: Английский

Citations

11
Exploring Extracellular Vesicles: A Novel Approach in Nonalcoholic Fatty Liver Disease DOI

Ana Isabel Vigil Medina,

Mengdie Shi,

Yanyan Wang

et al.

Journal of Agricultural and Food Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Nonalcoholic fatty liver disease (NAFLD) represents an increasing public health concern. The underlying pathophysiological mechanisms of NAFLD remains unclear, and as a result, there is currently no specific therapy for this condition. However, recent studies focus on extracellular vesicles (EVs) novelty in their role cellular communication. An imbalance the gut microbiota composition may contribute to progression NAFLD, making gut-liver axis promising target therapeutic strategies. This review aims provide comprehensive overview EVs NAFLD. Additionally, exosome-like nanovesicles derived from plants (PELNs) probiotics-derived (postbiotics) have demonstrated potential re-establish intestinal equilibrium modulate microbiota, thus offering alleviate via axis. Further research needed using multiple omics approaches comprehensively characterize cargo including protein, metabolites, genetic material packaged, biological activities diverse microbes plants.

Language: Английский

Citations

0
Unveiling NLR pathway signatures: EP300 and CPN60 markers integrated with clinical data and machine learning for precision NASH diagnosis DOI
Marwa Matboli, Noha E. El-Attar, Ibrahim Abdelbaky

et al.

Cytokine, Journal Year: 2025, Volume and Issue: 188, P. 156882 - 156882

Published: Feb. 8, 2025

Language: Английский

Citations

0
Obesity Management in Primary Care: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) - 2025 DOI Creative Commons
N. J. Pennings, Catherine Varney,

Stephanie L. Hines

et al.

Obesity Pillars, Journal Year: 2025, Volume and Issue: unknown, P. 100172 - 100172

Published: March 1, 2025

This collaboration from the Obesity Medicine Association (OMA) and American College of Osteopathic Family Physicians (ACOFP) examines obesity management a primary care perspective. joint perspective is based upon scientific evidence, clinical experience authors, peer review by OMA ACOFP leadership. The goal to identify answer sentinel questions about perspective, utilizing evidence-based publications, guided expert experience. disease that contributes both biomechanical complications most common cardiometabolic abnormalities encountered in care. Barriers impede optimal patients with include failure recognize as disease, lack accurate diagnosis, insufficient access treatment resources, inadequate training, time, adequate reimbursement adverse impact bias, stigma, discrimination. physicians are often first line healthcare setting. affords early intervention opportunities prevent and/or treat overweight obesity. Patient enhanced when clinicians risks benefits anti-obesity medications bariatric procedures, well long-term follow-up. Practical tools regarding 4 pillars nutrition therapy, physical activity, behavior modification, medical interventions (anti-obesity surgery) may assist improve health lives living

Language: Английский

Citations

0